Portfolio
HLEND seeks to build a diversified portfolio of senior secured private credit investments in resilient, market-leading, upper-middle market companies that operate primarily in non-cyclical sectors.
Data as of October 31, 2025
$24.4B
Investments at Fair Value
9.7%
Portfolio Yield at Fair Value1
93%
Private Investments2
97%
First Lien Exposure3
99%
Floating Rate4
$246M
Weighted Average EBITDA5
Portfolio Companies89
|
Company Name
|
Industry
|
Investment Type
|
Reference Rate & Spread11
|
Par Amount (thousands)
|
Amortized Cost (thousands)
|
Fair Value (thousands)
|
% of Total Portfolio
|
|---|---|---|---|---|---|---|---|
| Parfums Holding Company, Inc. (PDC Wellness) | Personal Care, Drug and Grocery Stores | 1st Lien Senior Secured Debt | S + 5.25% | $127,560 | 117,540 | 119,711 | 0.49% |
| DAPHNE S.P.A. (Dainese) | Personal Goods | 1st Lien Senior Secured Debt | E + 6.25% | € 45,354 | 47,923 | 41,831 | 0.17% |
| DAPHNE S.P.A. (Dainese) | Personal Goods | 1st Lien Senior Secured Debt | E + 6.75% | € 3,978 | 4,674 | 3,669 | 0.02% |
| S&S Holdings LLC (S&S Holdings) | Personal Goods | 1st Lien Senior Secured Debt | S + 5.00% | $11,880 | 11,725 | 11,595 | 0.05% |
| Spanx, LLC | Personal Goods | 1st Lien Senior Secured Debt | S + 5.25% | $5,000 | 2,098 | 1,619 | 0.01% |
| Spanx, LLC | Personal Goods | 1st Lien Senior Secured Debt | S + 5.50% | $28,875 | 28,611 | 24,931 | 0.10% |
| Advarra Holdings, Inc. (Advarra, Inc.) | Pharmaceuticals and Biotechnology | 1st Lien Senior Secured Debt | S + 4.50% | $215,613 | 207,950 | 211,384 | 0.87% |
| Amneal Pharmaceuticals LLC (Amneal Pharmaceuticals) | Pharmaceuticals and Biotechnology | 1st Lien Senior Secured Debt | S + 3.50% | $7,800 | 7,781 | 7,875 | 0.03% |
| Atlas Borrower, LLC (AnovoRx) | Pharmaceuticals and Biotechnology | 1st Lien Senior Secured Debt | S + 4.50% | $103,467 | 87,221 | 87,221 | 0.36% |
| Azurity Pharmaceuticals Inc (Azurity Pharmaceuticals) | Pharmaceuticals and Biotechnology | 1st Lien Senior Secured Debt | S + 7.00% | $253,434 | 245,585 | 246,995 | 1.01% |
| Cambrex Corporation | Pharmaceuticals and Biotechnology | 1st Lien Senior Secured Debt | S + 4.50% | $151,205 | 108,899 | 109,834 | 0.45% |
| Creek Feeder, L.P. (Catalent Inc.) | Pharmaceuticals and Biotechnology | Equity and other investments | $9,000 | 9,000 | 9,000 | 0.04% | |
| Creek Parent, Inc. (Catalent Inc.) | Pharmaceuticals and Biotechnology | 1st Lien Senior Secured Debt | S + 5.25% | $22,379 | (318) | (138) | 0.00% |
| Creek Parent, Inc. (Catalent Inc.) | Pharmaceuticals and Biotechnology | 1st Lien Senior Secured Debt | S + 5.00% | $120,542 | 118,815 | 119,801 | 0.49% |
| Creek Parent, Inc. (Catalent Inc.) | Pharmaceuticals and Biotechnology | 1st Lien Senior Secured Debt | S + 6.15% | $1,213 | 1,196 | 1,205 | 0.00% |
| Dechra Finance US LLC (Dechra) | Pharmaceuticals and Biotechnology | 1st Lien Senior Secured Debt | S + 3.25% | $4,146 | 4,137 | 4,162 | 0.02% |
| Endo Finance Holdings Inc (Endo) | Pharmaceuticals and Biotechnology | 1st Lien Senior Secured Debt | S + 4.00% | $8,133 | 8,064 | 8,097 | 0.03% |
| Gusto Aus Bidco Pty Ltd (iNova Pharmaceuticals) | Pharmaceuticals and Biotechnology | 1st Lien Senior Secured Debt | B + 4.75% | AUD 267,618 | 155,968 | 159,571 | 0.65% |
| Phantom Purchaser Inc (Pharmacord LLC) | Pharmaceuticals and Biotechnology | 1st Lien Senior Secured Debt | S + 4.75% | $116,344 | 99,717 | 99,885 | 0.41% |
| Syneos Health Inc (Syneos Health) | Pharmaceuticals and Biotechnology | 1st Lien Senior Secured Debt | S + 4.00% | $14,922 | 14,847 | 14,965 | 0.06% |
| WCG Intermediate Corp (WCG) | Pharmaceuticals and Biotechnology | 1st Lien Senior Secured Debt | S + 3.00% | $15,286 | 15,191 | 15,278 | 0.06% |
| ASSOCIATIONS INC. | Real Estate Investment and Services | 1st Lien Senior Secured Debt | S + 6.50% | $62,898 | 56,725 | 56,765 | 0.23% |
| Associations Finance, Inc. (Associations Inc.) | Real Estate Investment and Services | Unsecured Debt | 14.25% PIK | $13,746 | 13,704 | 13,746 | 0.06% |
| Link Apartments Opportunity Zone REIT, LLC | Real Estate Investment and Services | Other Secured Debt | S + 7.50% | $25,725 | 22,491 | 22,648 | 0.09% |
| Constellation Automotive Limited (BCA) | Retailers | 1st Lien Senior Secured Debt | SN + 6.25% | £43,803 | 56,535 | 57,122 | 0.23% |
Engage with HLEND
Start HereEngage with HLEND
Financial advisors can submit an inquiry using this form or engage with HPS at hlend@hpspartners.com. Individual investors should contact their financial advisor for more information.
Footnotes
- Computed as (a) the annual stated interest rate or yield plus the annual accretion of discounts and less any annual amortization of premiums, as applicable, on accruing (i) debt and (ii) other income producing securities, divided by (b) total accruing (i) debt and (ii) other income producing securities (at fair value). Actual yields earned over the life of each investment could differ materially from the yields presented above. Please refer to HLEND’s prospectus and filings, including Form 10-Q or Form 10-K for fair value disclosures.
- Private Investments represents level 3 investments in the investment portfolio where inputs to the valuation methodology are unobservable and significant to overall fair value measurement. Private investments includes investments in joint ventures.
- Based on the aggregate fair value of the investment portfolio as of October 31, 2025.
- Percentage based on aggregate fair value of accruing debt.
- Calculated with respect to all level 3 investments (or, with respect to weighted average loan to value, all level 3 debt investments) in the investment portfolio for which fair value is determined by the Investment Adviser (in its capacity as the investment adviser of HLEND, with assistance, at least quarterly, from a third-party valuation firm, and overseen by HLEND’s Board of Trustees), and excludes quoted assets and investments in joint ventures. In the case of weighted average EBITDA only, excludes investments with no reported EBITDA or where EBITDA, in the Investment Adviser’s judgement made in its discretion, was not a material component of the original investment thesis, such as loan-to-value-based loans, NAV-based loans or reorganized equity. Weighted average EBITDA is weighted based on the fair value of the total applicable level 3 investments. Loan to value is calculated as net debt through each respective investment tranche in which HLEND holds an investment divided by enterprise value or value of underlying collateral of the portfolio company. Weighted average loan to value is weighted based on the fair value of the total applicable level 3 debt investments. Excludes investments on non-accrual status as of October 31, 2024. Figures are derived from the most recent financial statements from portfolio companies.
- Includes “last out” portions of first lien senior secured loans.
- Secured debt at the holding company level.
- Based on FTSE / DJ Industry Classification Benchmark (“ICB”) sector definition. Totals may not sum due to rounding.
- All figures are as of October 31, 2025 unless otherwise indicated. % of total portfolio shown above is measured as total fair value of investments.
- Other includes structured finance investments.
- Contractual rates on preferred equity investments may represent preference accruals that are not recognized through investment income of the fund and as such are not included in the calculation of yield. The fair value of these investments may be influenced by the stated preference accrual or a minimum return threshold.